Gastrin-17 (G-17)

Gastrin is an acidic gastrointestinal hormone with the ability to stimulate gastric acid secretion, which plays an important role in regulating the function of the digestive tract and maintaining its structural integrity. More than 95% of biologically active gastrin in the human body is a-amidated gastrin, and the biologically active components in the blood circulation are mainly the two isomers of the large molecule gastrin-34 (G34) and the small molecule gastrin-17 (G17). 80% to 90% of them are Gastrin. Of these, 80% to 90% are G17. although G17 is the major product, G34 is the predominant circulating form of gastrin. g-17 is secreted only by G-cells in the gastric antrum, and is therefore considered an important indicator of the degree and extent of atrophic gastritis of the gastric mucosa. It is synthesized in 3 stages: pregastrin, glycine-extended gastrin and mature gastrin, the first 2 being unamidated intermediates and the mature gastrin being amidated gastrin. They stimulate gastric acid secretion by interacting with growth inhibitory cells and chromophores, and also promote the proliferation and differentiation of gastric mucosal cells.

KMD Bioscience, as a supplier of in vitro diagnostic raw materials, has been supplying the IVD industry with high-quality diagnostic antigens and antibodies for flow, colloidal gold, chemiluminescence, immunoturbidimetric and other assay platforms for over several years. KMD Bioscience's antibody and antigen diagnostic raw materials are strictly monitored during the R&D and production stages to ensure that the IVD raw materials are characterized by low inter/intra-batch variation, high specificity, wide linear range, good stability and high sensitivity.

The inventory of reagents associated with Gastrin-17 (astrin 17, G17) that KMD Bioscience can offer:

Biological Function of G17

Serum G-17 is an amidated gastrin synthesized and secreted by gastric sinus G-cells, and its secretion shows a strict negative feedback mechanism with gastric acid, which indirectly reflects the secretion function of mucosal glands or the number of glands.G-17 is one of the sensitive indicators of endocrine secretion in the gastric sinus, and it can indicate the atrophy status of the gastric sinus mucosa or the presence of abnormal proliferation. The level of serum G-17 depends on the acidity in the stomach and the number of G cells in the gastric sinus, and G-17 itself also plays a role in the development of gastric cancer. Combined with serum PG test, serum G-17 concentration test can diagnose atrophic gastritis in the gastric sinus (decreased G-17 level) or confined to the gastric body (increased G-17 level). Serum gastrin G-17 is significantly elevated in patients with gastric cancer and can be used as one of the screening indicators for early gastric cancer. When G-17, PGII and PGR are used for gastric cancer diagnosis, the accuracy of combined diagnosis is higher, among which the best diagnostic effect is G-17 combined with PGR, i.e., G-17>7 pmol/L and PGR<7.

Figure 2 Molecular structure of G17

Molecular mechanism of G17 associated with gastric cancer

Cancer is one of the most common cancers and most patients tend to die due to tumor metastasis. Gastrin is closely related to gastric cancer metastasis. As far as research shows gastrin is closely related to gastric cancer metastasis. The specific molecular mechanism is that gastrin and the Wnt/β-catenin inhibitor XAV939 have an effect on epithelial-mesenchymal transition (EMT) in SGC-7901 and MKN45 GC cell lines. It was determined that gastrin-17 significantly decreased the expression of E-calmodulin and upregulated the expression of Snail1 and N-calmodulin in gastric cancer (GC) cells. In addition, it also significantly increased the expression of Wnt3α in a dose-dependent manner and promoted invasion, proliferation and migration of GC cells, which were inhibited by XAV939. Thus, gastrin-17 induced epithelial-mesenchymal transition (EMT), migration and invasion of GC cells through the Wnt/β-catenin signaling pathway, suggesting that this gastrin/Wnt/β-catenin signaling axis is a therapeutic target for the prevention of gastric cancer metastasis.

KMD Bioscience has many years of experience in antibody drug research, with four platforms: monoclonal antibody production platform, polyclonal antibody production platform, phage antibody library technology platform, and antibody sequencing and application platform, and is committed to the rapid development and large-scale production of in vitro diagnostic proteins and antibodies. At the same time, KMD Bioscience is always looking for newer targets and is committed to providing customers with diversified antibody products.